JP2015194481A5 - - Google Patents

Download PDF

Info

Publication number
JP2015194481A5
JP2015194481A5 JP2015040187A JP2015040187A JP2015194481A5 JP 2015194481 A5 JP2015194481 A5 JP 2015194481A5 JP 2015040187 A JP2015040187 A JP 2015040187A JP 2015040187 A JP2015040187 A JP 2015040187A JP 2015194481 A5 JP2015194481 A5 JP 2015194481A5
Authority
JP
Japan
Prior art keywords
protein
fabp4
fabp5
expression level
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015040187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015194481A (ja
JP6223376B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2015040187A external-priority patent/JP6223376B2/ja
Priority to JP2015040187A priority Critical patent/JP6223376B2/ja
Priority to EP15769760.8A priority patent/EP3124966B1/en
Priority to US15/128,666 priority patent/US10132795B2/en
Priority to PCT/JP2015/056603 priority patent/WO2015146537A1/ja
Priority to CN201580015560.7A priority patent/CN106133519B/zh
Publication of JP2015194481A publication Critical patent/JP2015194481A/ja
Publication of JP2015194481A5 publication Critical patent/JP2015194481A5/ja
Publication of JP6223376B2 publication Critical patent/JP6223376B2/ja
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015040187A 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法 Expired - Fee Related JP6223376B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2015040187A JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法
CN201580015560.7A CN106133519B (zh) 2014-03-24 2015-03-06 Gip上升抑制剂的评价或选择方法
US15/128,666 US10132795B2 (en) 2014-03-24 2015-03-06 Method for evaluating or selecting agent for suppressing GIP level elevation
PCT/JP2015/056603 WO2015146537A1 (ja) 2014-03-24 2015-03-06 Ｇｉｐ上昇抑制剤の評価又は選択方法
EP15769760.8A EP3124966B1 (en) 2014-03-24 2015-03-06 Method for evaluating or selecting agent for suppressing gip level elevation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014060341 2014-03-24
JP2014060341 2014-03-24
JP2015040187A JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017144146A Division JP6514282B2 (ja) 2014-03-24 2017-07-26 Ｇｉｐ上昇抑制剤の評価又は選択方法

Publications (3)

Publication Number Publication Date
JP2015194481A JP2015194481A (ja) 2015-11-05
JP2015194481A5 true JP2015194481A5 (cg-RX-API-DMAC10.html) 2017-04-06
JP6223376B2 JP6223376B2 (ja) 2017-11-01

Family

ID=54195063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015040187A Expired - Fee Related JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法

Country Status (5)

Country Link
US (1) US10132795B2 (cg-RX-API-DMAC10.html)
EP (1) EP3124966B1 (cg-RX-API-DMAC10.html)
JP (1) JP6223376B2 (cg-RX-API-DMAC10.html)
CN (1) CN106133519B (cg-RX-API-DMAC10.html)
WO (1) WO2015146537A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6677455B2 (ja) * 2015-05-14 2020-04-08 花王株式会社 毛成長抑制剤の評価又は選択方法
CN114981446A (zh) * 2020-01-17 2022-08-30 日本乐敦制药株式会社 组织形态、组织功能控制剂的评价/筛选方法
CN116908157B (zh) * 2023-07-14 2026-05-29 杭州环特生物科技股份有限公司 一种评价药物和保健食品调节食欲的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
JP2004065194A (ja) * 2002-08-09 2004-03-04 Sumitomo Chem Co Ltd 脂肪細胞関連因子の分析方法
PT2403605E (pt) 2009-03-05 2015-08-05 Harvard College Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
JP5815928B2 (ja) 2009-07-16 2015-11-17 花王株式会社 血中ｇｉｐ濃度上昇抑制剤
JP5317919B2 (ja) 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP5328595B2 (ja) * 2009-10-05 2013-10-30 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
US9056066B2 (en) 2011-01-12 2015-06-16 Kao Corporation Agent for suppressing elevation of blood GIP level, agent for suppressing elevation of blood insulin level, agent for lowering blood triglyceride level after meal ingestion, and agent for suppressing elevation of blood glucose level
JP6026723B2 (ja) 2011-02-22 2016-11-16 花王株式会社 Ｇｉｐ上昇抑制剤
JP2012171914A (ja) 2011-02-22 2012-09-10 Kao Corp Ｇｉｐ上昇抑制剤
CN102961388A (zh) 2011-08-30 2013-03-13 三和淀粉工业株式会社 促进glp-1的分泌并且抑制gip的分泌的药剂

Similar Documents

Publication Publication Date Title
Xie et al. Cellular signalling of the receptor for advanced glycation end products (RAGE)
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
IL286465A (en) Electrode configurations for diagnosis of arrhythmlas
JP2017048194A5 (cg-RX-API-DMAC10.html)
MX2023014409A (es) Composiciones para usarse en el tratamiento de afecciones asociadas a una respuesta inflamatoria anomala.
JP2017526437A5 (ja) 遠隔虚血コンディショニングを行うシステムが組み込まれている医療装置、医療装置を動作させる方法、コンピュータ可読記憶媒体、台、及び自動体外式除細動器
JP2012035111A5 (cg-RX-API-DMAC10.html)
JP2014144959A5 (cg-RX-API-DMAC10.html)
WO2013011479A3 (en) Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression
EA201791747A1 (ru) 3-алкил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
TR201900057T4 (tr) Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler.
CY1115708T1 (el) Τοπικες συνθεσεις για τη διατηρηση ή την ανακτηση της ακεραιοτητας των βλεννογονων
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
JP2017039729A5 (cg-RX-API-DMAC10.html)
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
JP2014503607A5 (cg-RX-API-DMAC10.html)
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
JP2016521114A5 (cg-RX-API-DMAC10.html)
JP2016516985A5 (cg-RX-API-DMAC10.html)
JP2016528914A5 (cg-RX-API-DMAC10.html)
WO2015074010A8 (en) Compositions and methods for cardiac regeneration
JP2015530094A5 (cg-RX-API-DMAC10.html)
WO2014020444A3 (en) Methods and compositions for diagnosis and prognosis in breast cancer
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
WO2014022788A3 (en) Chicken astrovirus responsible for runting stunting syndrome